Fritextsökning
Innehållstyper
-
Getinge and Neobiomics received Swecare's export awards
Two companies received awards during Swecare's annual conference.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...
-
ZEISS unveils AI-powered Research Data Platform
Collaboration with Boehringer Ingelheim champions the future of personalized eye care.
-
Trump in new push to lower drug prices
U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
Quality solutions for medical device R&D applications
From R&D to the quality assurance of series production in medical device manufacturing.
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Meet us at Control 2025
Innovations that drive efficiency.
-
Ancient DNA provides new insights – “The immune system lost its job”
Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
ZEISS Quality Innovations at CONTROL
May 6-9, 2025 in Stuttgart.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
New drug to simplify treatment of hemophilia
A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
Akneläkemedel kan vara lösningen när håret faller av
En behandling som ursprungligen utvecklats mot akne har visat uppseendeväckande resultat i fas III inom ett helt annat område: manligt håravfall.
-
Sneak Peek of ZEISS Metrology Expert Tips Season 2
The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
ZEISS introduces the new Smartzoom 100
The future of digital microscopy for efficient optical inspections.
-
We desire talent to come here, but are we genuinely welcoming them?
Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...
-
Conference recordings now available
Don't miss out on insights from leading experts.
BREAKING